Detalhe da pesquisa
1.
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Invest New Drugs
; 34(5): 625-35, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27350064
2.
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Invest New Drugs
; 33(6): 1206-16, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377590
3.
Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
Br J Haematol
; 166(1): 91-7, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24673609
4.
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Invest New Drugs
; 29(1): 144-53, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19714296
5.
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Am J Hematol
; 86(7): 573-8, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21630305
6.
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
Anticancer Drugs
; 21(8): 777-84, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20634689
7.
A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.
J Thorac Oncol
; 16(10): e95, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34561049
8.
Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.
PLoS One
; 9(9): e107455, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25250715
9.
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
J Clin Oncol
; 31(25): 3127-32, 2013 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23897968
10.
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
J Thorac Oncol
; 8(7): 930-9, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23722170
11.
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Lung Cancer
; 81(3): 428-434, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23790468
12.
Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.
Br J Clin Pharmacol
; 64(4): 458-68, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17555467